Inclusion Criteria:

- Patient must have histologically proven diagnosis of Non-Squamous NSCLC. NSCLC
histologies that will be included in this trial will be adenocarcinoma, large cell
carcinoma and adeno-squamous carcinoma. Patients with bronchioloalveolar carcinoma
(BAC) will be also included in this trial.

- Patients must be 70 years of age or older.

- Patient must have either stage IIIB disease with malignant pleural effusion or stage
IV disease. All patients must have measurable disease. Evaluable disease will be
separately outlined and elucidated.

- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of
either 0 or 1.

- Patient must have adequate renal function with a serum creatinine level of less than
1.5mg/dl and patient should have a calculated creatinine clearance of more than
45ml/min.

- Patient must have adequate hepatic function with a serum bilirubin level of less that
3mg/dl, and an alkaline phosphatase, Alanine Amino Transferase (ALT) and Aspartate
Amino Transferase (AST) of less than three times the upper limit of normal

- Patient must also have evidence of adequate bone marrow function with an absolute
neutrophil count of more than 1, 500 cells per deciliter and a platelet count of more
than 100,000 per deciliter.

- Patients must be more than 28 days since prior open biopsy; more than 7 days since
prior fine-needle aspiration; more than 7 days since prior core biopsy; more than 28
days since prior surgery.

- Patients must be able to take dexamethasone, folic acid and vitamin B-12
supplementation.

- All patients must sign informed consent that will detail the investigational nature
of the study in accordance with the institutional and federal guidelines.

Exclusion Criteria:

- Lung carcinoma of squamous cell histology or any histology in close proximity to a
major vessel, with or without cavitation.

- Patients with hypercalcemia (corrected calcium of more than 11 mg/dl) will be
excluded.

- Patients with history of hemoptysis, hematemesis, coagulopathy or thrombosis will be
excluded.

- Patients requiring anticoagulation for any reason will be excluded.

- Patients who recently have an acute infection.

- History of palliative radiation therapy within 2 weeks.

- Blood pressure of >150/100 Millimeter Mercury(mmHg).

- Currently ongoing unstable angina.

- New York Heart Association (NYHA) Grade II or greater congestive heart failure.

- History of myocardial infarction within 6 months.

- History of stroke within 6 months.

- Clinically significant peripheral vascular disease.

- Presence of central nervous system or brain metastases.

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 0, anticipation of need for major surgical procedure during the course
of the study.

- Minor surgical procedures such as fine needle aspirations or core biopsies within 7
days prior to Day 0.

- Pregnant (positive pregnancy test) or lactating.

- Urine calculated creatinine clearance of less than 45ml/minute and a urinary protein.
Creatinine ratio of more than 1.

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to Day 1.

- Serious, non-healing wound, ulcer, or bone fracture.

- Inability to comply with study and/or follow-up procedures.